December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Nitric Oxide Scavenger AMD6221 Suppresses Endotoxin-Induced Uveitis (EIU) in Rabbits
Author Affiliations & Notes
  • JB Allen
    APR Coll of Veterinary Med NC State Col Vet Med Raleigh NC
  • KA Pittman
    APR Coll of Veterinary Med NC State Col Vet Med Raleigh NC
  • T Keng
    VitaResc Biotech Inc Rtp NC
  • BC Gilger
    APR Coll of Veterinary Med NC State Col Vet Med Raleigh NC
  • CT Privalle
    VitaResc Biotech Inc Rtp NC
  • SP Fricker
    AnorMed Langley BC Canada
  • Footnotes
    Commercial Relationships   J.B. Allen, None; K.A. Pittman, None; T. Keng, VitaResc Biotech, Inc E; B.C. Gilger, None; C.T. Privalle, VitaResc Biotech, Inc. E; S.P. Fricker, AnorMed, Inc E. Grant Identification: NIH Grant EY11364
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3976. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      JB Allen, KA Pittman, T Keng, BC Gilger, CT Privalle, SP Fricker; Nitric Oxide Scavenger AMD6221 Suppresses Endotoxin-Induced Uveitis (EIU) in Rabbits . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3976.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Nitric oxide (NO) is an important mediator in ocular inflammation. We have shown that overproduction of NO is involved in EIU in rabbits. Administration of NOS inhibitors can either suppress or exacerbate uveitis depending on the specificity of the inhibitors and timing of administration (Exp Eye Res 62:21-28). The current study evaluated a NO scavenger (ruthenium III polyaminocarboxylate; [Ru(H3dtpa)Cl], AMD6221) as an innovative treatment on development and severity of uveitis. Methods: Right eyes of New Zealand white rabbits (n=12/group) were injected intravitreally with LPS (20 ng) and AMD6221 (3.85 mM) or control vehicle (AMD3689, the stable nitrosylated derivative of AMD6221; 3.85 mM) or saline vehicle; left eyes received saline and AMD6221 or AMD3689 or saline vehicle. Six hours later, eyes that received injections of AMD6221 received a second AMD6221 injection; eyes that received AMD3689 or saline vehicle also received second injections. Uveitic responses were assessed over 24 hours by biomicroscopic examination. Aqueous flare (AF) and iridal hyperemia (IH) were scored on a scale of 0-4. After euthanasia, aqueous humors were aspirated, protein levels and total cell counts measured, and eyes processed for histologic analysis. Results: Co-administration of AMD6221 with LPS followed by administration alone 6 hours later, resulted in a decrease in both AF (2.50.58 vs 0.50.6; P<0.05) and IH (2.5 0.41 vs 0.750.5; P<0.05), compared to LPS+vehicle. In addition, AMD6221 decreased protein extravasation by ∼60% and leukocyte infiltration by ≷90%. Histological analysis confirmed decreased inflammation in LPS+AMD6221-treated eyes. Treatment with the control nitrosylated derivative did not significantly affect the uveitic response. AMD6221 administered alone caused no abnormal ocular changes. Conclusions: NO scavengers that mediate the clearance of harmful levels of NO, preserving beneficial functions of NO, may represent an alternative approach for the treatment of uveitis and other NO-based ocular diseases. Support: NIH grant #EY11364 and funds from the State of North Carolina. CR: E.

Keywords: 491 nitric oxide • 612 uveitis-clinical/animal model • 437 inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.